Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|April 15, 2021
Inverse probability of censoring weighting for visual predictive checks of time-to-event models with time-varying covariatesChristian Bartels, Thomas Dumortier
CPT: Pharmacometrics & Systems Pharmacology|May 1, 2021
Exposure-response modeling for extrapolation from adult to pediatric patients who differ with respect to prognostic factors: Application to everolimusThomas Dumortier, Günter Heimann, Martin Fink
Clinical Trials (London, England)|July 8, 2025
Dose-response characterization: A key to success in drug developmentFrank Bretz, Björn Bornkamp, Thomas Dumortier
Journal of Pharmacokinetics and Pharmacodynamics|November 15, 2025
A note on phase I interleaved versus parallel group ascending dose designs for concentration-QTc analysesGünter Heimann, Thomas Dumortier, Karin Meiser
CPT: Pharmacometrics & Systems Pharmacology|March 2, 2026
Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response AnalysesSebastiaan C Goulooze, Camille Vong, Chuanpu Hu, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 24, 2024
Nonlinear mixed-effects modeling as a method for causal inference to predict exposures under desired within-subject dose titration schemesChristian Bartels, Martina Scauda, Neva Coello, et al.
Clinical Pharmacology and Therapeutics|June 2, 2025
Model-Informed Drug Development-Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial SpondyloarthritisThomas Dumortier, Guillermo Valenzuela, Melvin Churchill, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2024
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 StudyAlan Kivitz, Liliana Sedova, Melvin Churchill, et al.
The Lancet. Neurology|June 9, 2012
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human studyBengt Winblad, Niels Andreasen, Lennart Minthon, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|October 12, 2023
Qualifying a Novel Clinical Trial Endpoint (iBOX) Predictive of Long-Term Kidney Transplant OutcomesAmanda Klein, Alexandre Loupy, Mark Stegall, et al.
Pageof 2